arrow_back Back Filing freshness 10-K Q4 FY2026 SEC EDGAR

BIO-TECHNE Corp

TECH
$72.67 ▼ -0.06 (-0.09%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
70 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
75
Health
Good
Bullish
auto_awesome

Analytical Summary

BIO-TECHNE Corp shows strong fundamentals with top-quartile Profit Margin (%) and Operating Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap —
Dividend Yield —
Revenue Growth 1.3% ↗
Op. Margin 23.1% ↘
ROIC 2.7% ↗
FCF / Share None
Trailing P/E 207.6x
Price / Book 5.4x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

70-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$321.19M
↑ +1.3% —
Net Income Profit after all expenses
$51.05M
↑ +126.0% —
Operating Margin Operating profit as % of sales
23.1%
↓ -4.6% 85th
FCF / Share Free cash flow per share
$0.50
↑ +1.1% —
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability ↓
82
Returns →
58
Financial Health ↓
84
Cash Quality ↑
79

Dividend History

Dividend / share · sourced from SEC filings
$0.32 Latest / share
+0.0% YoY
+0.1% 12-yr CAGR

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 19 years · 70 quarters